Mizuho raised the firm’s price target on Immuneering (IMRX) to $10 from $8 and keeps an Outperform rating on the shares. The company announced positive updated Phase 2a data for lead asset IMM-1-104 in first-line pancreatic cancer in combination with modified Gemcitabine, a standard-of-care treatment, the analyst tells investors in a research note. The firm came away “very impressed” by this first look at the overall survival and progression-free survival data.
Claim 55% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on IMRX:
- Immuneering’s Promising Clinical Developments and Future Prospects Justify Buy Rating
- Morning Movers: Verve skyrockets after deal to be acquired by Eli Lilly
- Immuneering Announces Promising Phase 2a Trial Results
- Immuneering’s atebimetinibin shows positive survival data in pancreatic cancer
- Immuneering Elects New Directors at Annual Meeting